DRC will also provide a $15 million milestone payment in 2012 should certain royalty recognition levels be met. Peg-Intron (peginterferon alpha-2b), is approved for the treatment of hepatitis C and is marketed worldwide by Schering-Plough.
Speaking on behalf of DRC, Paul Kirkconnell, MD, said: “We believe that Peg- Intron is one of the most advanced medications to treat hepatitis C on the market today. With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon.”
Peg-Intron is a Peg-enhanced version of Schering-Plough's alpha interferon product, Intron A, which is used both as a monotherapy and in combination with Rebetol (ribavirin) capsules for the treatment of chronic hepatitis C.